Table 1.
Characteristics of subjects and assays according to CSF Aβ42 concentrations.
| Low(n = 10) | Intermediate(n = 10) | High(n = 10) | |
|---|---|---|---|
| Female (%) | 3 (30%) | 7 (70%) | 3 (30%) |
| Age, yr (SD) | 72.7 (7.9) | 65.5 (8.5) | 72.5 (8.4) |
| Diagnosis | |||
| Normal cognition | 3 | 2 | 4 |
| Mild cognitive impairment | 4 | 2 | 6 |
| AD dementia | 2 | 4 | 0 |
| Other dementia | 1 | 2 | 0 |
| Aβ42CLEIA, pg/mL (SD) | 219.5 (50.2) | 327.7 (51.0) | 821.5 (194.4) |
| Aβ42Luminex, pg/mL (SD) | 105.7 (29.3) | 173.3 (42.4) | 400.9 (68.6) |
| Aβ42ELISA, pg/mL (SD) | 265.9 (56.6) | 363.3 (66.1) | 698.0 (97.6) |
| t-TauLuminex, pg/mL (SD) | 51.2 (50.9) | 64.3 (62.1) | 33.5 (7.8) |
| p-TauLuminex, pg/mL (SD) | 22.9 (24.7) | 42.2 (48.8) | 7.1 (6.9) |
| Intra-assay CV (repeatability) | |||
| CLEIA | 2.4% | 2.1% | 1.4% |
| Luminex | 12.0% | 13.3% | 9.4% |
| ELISA | 3.3% | 3.6% | 3.1% |
| Inter-assay CV (intermediate precision) | |||
| CLEIA | 10.1% | 7.1% | 4.0% |
| Luminex | 11.8% | 11.5% | 8.8% |
| ELISA | 14.6% | 9.8% | 7.8% |